181 related articles for article (PubMed ID: 27764830)
21. An Incidental Malignant Gastrointestinal Neuroectodermal Tumor of the Stomach: A Rare Case Report and a Literature Review.
Youssef B; Mohamed RM; Vahhabaghai P; Asberry D
Cureus; 2022 Aug; 14(8):e28042. PubMed ID: 36120228
[TBL] [Abstract][Full Text] [Related]
22. Potential prognostic determinants for FET::CREB fusion-positive intracranial mesenchymal tumor.
Mezzacappa FM; Smith FK; Zhang W; Gard A; Cabuk FK; Gonzalez-Gomez I; Monforte HL; Liang J; Singh O; Quezado MM; Aldape KD; Gokden M; Bridge JA; Chen J
Acta Neuropathol Commun; 2024 Jan; 12(1):17. PubMed ID: 38291529
[TBL] [Abstract][Full Text] [Related]
23. Malignant Gastrointestinal Neuroectodermal Tumor: Clinicopathologic, Immunohistochemical, and Molecular Analysis of 19 Cases.
Chang B; Yu L; Guo WW; Sheng WQ; Wang L; Lao I; Huang D; Bai QM; Wang J
Am J Surg Pathol; 2020 Apr; 44(4):456-466. PubMed ID: 31651526
[TBL] [Abstract][Full Text] [Related]
24. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
[TBL] [Abstract][Full Text] [Related]
25. Malignant gastrointestinal neuroectodermal tumor: a case report and review of the literature.
Alyousef MJ; Alratroot JA; ElSharkawy T; Shawarby MA; Al Hamad MA; Hashem TM; Alsayyah A
Diagn Pathol; 2017 Mar; 12(1):29. PubMed ID: 28320420
[TBL] [Abstract][Full Text] [Related]
26. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
[TBL] [Abstract][Full Text] [Related]
27. STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion.
Subbiah V; McMahon C; Patel S; Zinner R; Silva EG; Elvin JA; Subbiah IM; Ohaji C; Ganeshan DM; Anand D; Levenback CF; Berry J; Brennan T; Chmielecki J; Chalmers ZR; Mayfield J; Miller VA; Stephens PJ; Ross JS; Ali SM
J Hematol Oncol; 2015 Jun; 8():66. PubMed ID: 26062823
[TBL] [Abstract][Full Text] [Related]
28. A rare case of clear cell sarcoma with 4 types of EWSR1-ATF1 fusions detected not in primary site but in metastatic site.
Tsukamoto Y; Nakata Y; Futani H; Fukunaga S; Kajimoto K; Hirota S
Pathol Res Pract; 2013 Dec; 209(12):803-7. PubMed ID: 23953591
[TBL] [Abstract][Full Text] [Related]
29. EWS-CREB1: a recurrent variant fusion in clear cell sarcoma--association with gastrointestinal location and absence of melanocytic differentiation.
Antonescu CR; Nafa K; Segal NH; Dal Cin P; Ladanyi M
Clin Cancer Res; 2006 Sep; 12(18):5356-62. PubMed ID: 17000668
[TBL] [Abstract][Full Text] [Related]
30. [Clear cell sarcoma or gastrointestinal neuroectodermal tumor (GNET) of the tongue? Case report and review of the literature of an extremely rare tumor localization].
Breton S; Dubois M; Geay JF; Gillebert Q; Tordjman M; Guinebretière JM; Denoux Y
Ann Pathol; 2019 Apr; 39(2):167-171. PubMed ID: 30554833
[TBL] [Abstract][Full Text] [Related]
31. Fine Needle Aspiration Cytology of Malignant Digestive System Gastrointestinal Neuroectodermal Tumor in a Lymph Node Metastasis from a Previously Diagnosed Liver Primary: A Case Report and Review of Literature.
Gadde R; Linos K; Lisovsky M; Kerrigan T; Loehrer AP; Kasumova G; Kerr DA; Liu X
Diagn Cytopathol; 2021 Mar; 49(3):E130-E136. PubMed ID: 32975903
[TBL] [Abstract][Full Text] [Related]
32. Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement.
Schwab R; Petak I; Kollar M; Pinter F; Varkondi E; Kohanka A; Barti-Juhasz H; Schönleber J; Brauswetter D; Kopper L; Urban L
Lung Cancer; 2014 Jan; 83(1):109-11. PubMed ID: 24192513
[TBL] [Abstract][Full Text] [Related]
33. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
[TBL] [Abstract][Full Text] [Related]
34. Malignant gastrointestinal neuroectodermal tumor-A case report.
Harshavardhini S; Saishalini CN; Pavithra V; Shah NM; Sankar S
Indian J Pathol Microbiol; 2021; 64(2):373-375. PubMed ID: 33851638
[TBL] [Abstract][Full Text] [Related]
35. A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: a case report.
Zhou N; Schäfer R; Li T; Fang M; Liu L
BMC Cancer; 2018 Aug; 18(1):842. PubMed ID: 30134855
[TBL] [Abstract][Full Text] [Related]
36. Endobronchial pulmonary angiomatoid fibrous histiocytoma: two cases with EWSR1-CREB1 and EWSR1-ATF1 fusions.
Thway K; Nicholson AG; Wallace WA; Al-Nafussi A; Pilling J; Fisher C
Am J Surg Pathol; 2012 Jun; 36(6):883-8. PubMed ID: 22588066
[TBL] [Abstract][Full Text] [Related]
37. Activity of Entrectinib in a Patient With the First Reported
Sigal D; Tartar M; Xavier M; Bao F; Foley P; Luo D; Christiansen J; Hornby Z; Maneval EC; Multani P
J Natl Compr Canc Netw; 2017 Nov; 15(11):1317-1322. PubMed ID: 29118225
[TBL] [Abstract][Full Text] [Related]
38. Durable response to crizotinib in metastatic angiomatoid fibrous histiocytoma with EWSR1-CREB1 fusion and ALK overexpression.
Ngo C; Grinda T; Boilève A; Levy A; Le Pechoux C; Haddag L; Valent A; Lazure T; Briand S; Honoré C; Faron M; Mir O; Bahleda R; Verret B; Le Cesne A
Ann Oncol; 2022 Aug; 33(8):848-850. PubMed ID: 35568279
[No Abstract] [Full Text] [Related]
39. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.
Fontana D; Ceccon M; Gambacorti-Passerini C; Mologni L
Cancer Med; 2015 Jul; 4(7):953-65. PubMed ID: 25727400
[TBL] [Abstract][Full Text] [Related]
40. Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.
Megiorni F; McDowell HP; Camero S; Mannarino O; Ceccarelli S; Paiano M; Losty PD; Pizer B; Shukla R; Pizzuti A; Clerico A; Dominici C
J Exp Clin Cancer Res; 2015 Oct; 34():112. PubMed ID: 26445453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
